Underwood, E;
Dunkle, LM;
Madhi, SA;
Gay, CL;
Heath, PT;
Kotloff, KL;
Smith, K;
Chau, G;
Galbiati, S;
McGarry, A;
et al.
Underwood, E; Dunkle, LM; Madhi, SA; Gay, CL; Heath, PT; Kotloff, KL; Smith, K; Chau, G; Galbiati, S; McGarry, A; Woo, W; Cho, I; Alves, K; Áñez, G; Bennett, C; Shinde, V; Fries, L; Mallory, RM; Glenn, GM; Toback, S
(2023)
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.
Expert Rev Vaccines, 22 (1).
pp. 501-517.
ISSN 1744-8395
https://doi.org/10.1080/14760584.2023.2218913
SGUL Authors: Heath, Paul Trafford
|
PDF
Published Version
Available under License Creative Commons Attribution Non-commercial. Download (6MB) | Preview |
|
![]() |
Microsoft Word (.docx) (Supplementary figures)
Published Version
Available under License Creative Commons Attribution Non-commercial. Download (327kB) |
Abstract
INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and mortality worldwide. As SARS-CoV-2 moves into endemic status, vaccination remains a key element in protecting the health of individuals, societies, and economies worldwide. AREAS COVERED: NVX-CoV2373 (Novavax, Gaithersburg, MD) is a recombinant protein vaccine composed of SARS-CoV-2 spike trimer nanoparticles formulated with saponin-based Matrix-M™ adjuvant (Novavax, Gaithersburg, MD). NVX-CoV2373 is authorized for emergency use in adults and adolescents aged ≥12 years in the United States and numerous other countries. EXPERT OPINION: In clinical trials, NVX-CoV2373 showed tolerable reactogenicity and favorable safety profiles characterized by mostly mild-to-moderate adverse events of short duration and by low rates of severe and serious adverse events comparable to those seen with placebo. The two-dose primary vaccination series resulted in robust increases in anti-spike protein immunoglobulin G, neutralizing antibody titers, and cellular immune responses. NVX-CoV2373 vaccination was associated with complete protection against severe disease and a high (90%) rate of protection against symptomatic disease in adults, including symptomatic disease caused by SARS-CoV-2 variants. Additionally, the NVX-CoV2373 adjuvanted recombinant protein platform offers a means to address issues of COVID-19 vaccination hesitancy and global vaccine equity.
Item Type: | Article | ||||||||
---|---|---|---|---|---|---|---|---|---|
Additional Information: | © 2023 Novavax, Inc. Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. | ||||||||
Keywords: | COVID-19, Matrix-M adjuvant, NVX-CoV2373, SARS-CoV-2, clinical trial, coronavirus, prevention, protein-based vaccine, vaccination, Adolescent, Adult, Humans, Antibodies, Neutralizing, Antibodies, Viral, COVID-19, COVID-19 Vaccines, Immunogenicity, Vaccine, SARS-CoV-2, Vaccines, Child, Humans, Vaccines, Antibodies, Viral, Adolescent, Adult, Child, Antibodies, Neutralizing, Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, clinical trial, coronavirus, COVID-19, Matrix-M adjuvant, prevention, protein-based vaccine, SARS-CoV-2, vaccination, NVX-CoV2373, 1103 Clinical Sciences, 1117 Public Health and Health Services, Virology | ||||||||
SGUL Research Institute / Research Centre: | Academic Structure > Infection and Immunity Research Institute (INII) | ||||||||
Journal or Publication Title: | Expert Rev Vaccines | ||||||||
ISSN: | 1744-8395 | ||||||||
Language: | eng | ||||||||
Dates: |
|
||||||||
Publisher License: | Creative Commons: Attribution-Noncommercial 4.0 | ||||||||
Projects: |
|
||||||||
PubMed ID: | 37246757 | ||||||||
Web of Science ID: | WOS:001000633200001 | ||||||||
Go to PubMed abstract | |||||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/115498 | ||||||||
Publisher's version: | https://doi.org/10.1080/14760584.2023.2218913 |
Statistics
Actions (login required)
![]() |
Edit Item |